Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)

BACKGROUND: Emicizumab is a subcutaneously administered humanized, bispecific, monoclonal antibody approved for prophylaxis in people with hemophilia A. METHODS: HAVEN 5 (NCT03315455) is a randomized, open‐label, phase 3 study of individuals aged ≥12 years with severe hemophilia A without factor VII...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Renchi, Wang, Shujie, Wang, Xuefeng, Sun, Jing, Chuansumrit, Ampaiwan, Zhou, Jianfeng, Schmitt, Christophe, Hsu, Wanling, Xu, Jeffrey, Li, Lindong, Chang, Tiffany, Zhao, Xielan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902287/
https://www.ncbi.nlm.nih.gov/pubmed/35284778
http://dx.doi.org/10.1002/rth2.12670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902287/
https://www.ncbi.nlm.nih.gov/pubmed/35284778
http://dx.doi.org/10.1002/rth2.12670

Ejemplares similares